Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

European Medical Group Changes Drug Data-Release Policy After Criticism

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/22/2012 | 06:28pm CET
   By Peter Loftus 
   Of  
 

A European medical society has changed its plans for releasing results of clinical studies of liver-disease therapies after some critics said the original plan would have amounted to selective disclosure to certain investors.

The studies are expected to include potentially market-moving results of trials involving hepatitis C drugs in development at Abbott Laboratories (>> Abbott Laboratories), Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) and Gilead Sciences Inc. (GILD).

The European Association for the Study of the Liver now plans to publicly release summaries of most of the studies online April 4, two weeks ahead of the association's International Liver Congress meeting in Barcelona.

Under the new policy, certain studies selected to be highlighted by EASL's press office won't be made available publicly until the date and time of their presentation at the conference, which runs April 18-22. EASL didn't say which studies will be selected. However, EASL said they won't be made available in advance to non-media conference participants before the embargoes lift.

Previously, EASL had planned to make the summaries available online Thursday, but only accessible to EASL members and those registered for the conference, which includes analysts and investors. EASL also previously planned to prohibit media registered to attend the conference from reporting on the summaries until the conference.

Critics of the policy, including TheStreet.com reporter Adam Feuerstein, said the original plans amounted to selective disclosure by providing material information to people who paid to attend the conference, while unfairly leaving others in the dark.

"EASL is making these changes in light of recent criticism of its proposed policy, which suggests that 'selective distribution' of officially accepted clinical data in advance of the Congress would make our proposed embargo policy untenable," EASL said in a written statement Thursday.

The presentation of drug data at medical meetings has long posed a conundrum for companies and investors. Some conferences have made changes in their policies to address concerns.

The American Society of Clinical Oncology, for instance, used to distribute study summaries to participants at its annual meeting weeks ahead of the conference, but prohibit media from reporting the contents until the conference.

ASCO has since changed its policy so that now most summaries are posted publicly online a few weeks before the annual scientific meeting, while certain featured studies aren't publicly disclosed until the meeting.

Scott Gottlieb, a physician and resident fellow at the American Enterprise Institute who has criticized certain medical meeting embargo policies, said EASL did the right thing.

"I think the days of conferences engaging in selective release of important study results are probably over," he said. "ASCO yielded to this truth, EASL did, and I suspect other major conferences will be that much more reluctant to now buck these precedents."

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

Stocks mentioned in the article : Abbott Laboratories, Bristol Myers Squibb Co.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBOTT LABORATORIES
07:38p ABBOTT LABORATORIES : Trademark Application for "FLEXIFLO" Filed by Abbott Labor..
01/18 ABBOTT : Announces European Launch of the Proclaim(TM) DRG Neurostimulation Syst..
01/17 ABBOTT LABORATORIES : New Data Confirms Abbott's Dorsal Root Ganglion Stimulatio..
01/16 ABBOTT LABORATORIES : Global Prebiotics Market 2017 - Abbott Laboratories, GNC, ..
01/12 ABBOTT LABORATORIES : Announces U.S. Launch and First Commercial Use of the New ..
01/12 ABBOTT : Announces U.S. Launch and First Commercial Use of the New EnSite(TM) Pr..
01/12 ABBOTT LABORATORIES : Trademark Application for "FRUITIFIED" Filed by Abbott Lab..
01/12 ABBOTT LABORATORIES : Trademark Application for "ZONEPERFECT INDULGENCE" Filed b..
01/12 ABBOTT LABORATORIES : ' Trademark Application for "KNOWLEDGE LADDERS" Filed
01/12 ABBOTT LABORATORIES : $30,000 Federal Contract Awarded to Abbott Laboratories
More news
Sector news : Pharmaceuticals - NEC
04:33p Davos CEOs 'go local' on supply chain in Trump era
11:15a GSK grabs Astra executive to replace pharma head
10:40aDJGLAXOSMITHKLINE : Global Pharmaceuticals President Abbas Hussain to Leave -- Upd..
08:48aDJBusiness Watch -- WSJ
08:28aDJGLAXOSMITHKLINE : Global Pharmaceuticals President Abbas Hussain to Leave
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/18 3 COMPANIES WITH RECENT DIVIDEND INC : Review Using Dividend Safety Model - Janu..
01/18 Valeant Gives Up Gains
01/18 Abbott launches new neurostimulation system in Europe
01/17 DGI FOR THE DIY : 2016 Portfolio Review
01/16 Bummed About Your Abbott Labs Dividend? Here's How To Boost It
Advertisement
Financials ($)
Sales 2016 20 898 M
EBIT 2016 4 077 M
Net income 2016 1 666 M
Debt 2016 4 126 M
Yield 2016 2,54%
P/E ratio 2016 22,83
P/E ratio 2017 17,36
EV / Sales 2016 3,56x
EV / Sales 2017 3,35x
Capitalization 70 360 M
More Financials
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 46,7 $
Spread / Average Target 15%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Senior VP-Finance
Randel W. Woodgrift VP-Vascular, Manufacturing, Research & Development
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES6.12%70 360
JOHNSON & JOHNSON-0.44%312 045
ROCHE HOLDING LTD.1.29%203 230
PFIZER INC.-1.39%194 369
NOVARTIS AG-3.71%189 507
MERCK & CO., INC.3.91%168 654
More Results